ブロモクリプチンによるトラウマ後耐性性交感性多動症の治療:症例報告
Min-Seok Woo1, Seong-Hyun Park1, Jeong-Hyun Hwang1
1Department of Neurosurgery, Kyungpook National University School of Medicine, Daegu, Korea.
Journal of trauma and injury
|September 5, 2025
まとめ
この症例報告は,脳外傷後の耐性性交感性多動性症 (PSH) のブロモクリプチン治療の成功例を詳細に説明しています. ブロモクリプチンは重度のPSH症状を効果的に管理し,新しい治療法を提供しました.
科学分野:
- 神経科学
- 神経科学
- トラウマケア
背景:
- トラウマ性脳損傷 (TBI) は複雑な神経学的合併症につながる可能性があります.
- パロキシズム性交感性多動性 (PSH) は,自律的調節障害によって特徴づけられる希少だが重篤な状態である.
- 耐火性PSHは,標準的な治療法に抵抗する多くの管理上の課題をもたらします.
研究 の 目的:
- TBIの後に耐火性PSHのユニークなケースを記述します.
- 重度のPSH管理におけるブロモクリプチンの有効性を評価する.
- PSHに対する標的型介入の重要性を強調する.
主な方法:
- TBIと耐火性PSHの19歳の女性患者が治療されました.
- PSHの診断は,パロキシズマ・シンパティック・ハイパーアクティビティ・アセスメント・メジャーを用いて確認された.
- ブロモクリプチンを投与し,症状に応じて投与量を調整した.
主要な成果:
- ブロモクリプチンの治療は,PSHエピソードの頻度と重度の急速かつ有意な減少につながった.
- ブロモクリプチン治療の6日以内にPSH症状の完全な解消が達成されました.
- 治療中止後の10ヶ月のフォローアップ期間中,患者は症状なしでした.
結論:
- ブロモクリプチンは,特にTBI後の耐火性PSHに対する効果的な治療法です.
- 早期発見と標的型治療は,PSHの管理に不可欠です.
- このケースは,従来のPSH療法が失敗したときの価値ある代替品としてブロモクリプチンを支持しています.
関連する概念動画
01:24Parkinson's Disease: Treatment
375
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
375
01:26Psychosis: Goals of Pharmacotherapy
208
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
208
01:24Mania and Antimanic Drugs: Overview
318
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
318
01:26Cholinergic Antagonists: Therapeutic Uses
866
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
866
01:26COPD: Management Using Bronchodilators and Corticosteroids
300
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
300
01:15REM Sleep Behavior Disorder
378
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
378